Form 8-K - Current report:
SEC Accession No. 0001193125-25-003214
Filing Date
2025-01-08
Accepted
2025-01-08 07:50:01
Documents
16
Period of Report
2025-01-08
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d887412d8k.htm   iXBRL 8-K 28708
2 EX-23.1 d887412dex231.htm EX-23.1 3287
3 EX-99.1 d887412dex991.htm EX-99.1 24087
7 GRAPHIC g887412g0107150915201.jpg GRAPHIC 18330
  Complete submission text file 0001193125-25-003214.txt   213665

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA vir-20250108.xsd EX-101.SCH 2834
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE vir-20250108_lab.xml EX-101.LAB 17993
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vir-20250108_pre.xml EX-101.PRE 11251
18 EXTRACTED XBRL INSTANCE DOCUMENT d887412d8k_htm.xml XML 3630
Mailing Address 1800 OWENS STREET SUITE 900 SAN FRANCISCO CA 94158
Business Address 1800 OWENS STREET SUITE 900 SAN FRANCISCO CA 94158 415-906-4324
Vir Biotechnology, Inc. (Filer) CIK: 0001706431 (see all company filings)

EIN.: 812730369 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39083 | Film No.: 25516600
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)